- Home
- PBFS vs NYXH Comparison
PBFS vs NYXH Comparison
Compare PBFS & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBFS
- NYXH
- Stock Information
- Founded
- PBFS 1889
- NYXH 2009
- Country
- PBFS United States
- NYXH Belgium
- Employees
- PBFS N/A
- NYXH N/A
- Industry
- PBFS Banks
- NYXH Medical/Dental Instruments
- Sector
- PBFS Finance
- NYXH Health Care
- Exchange
- PBFS Nasdaq
- NYXH Nasdaq
- Market Cap
- PBFS 311.6M
- NYXH 231.0M
- IPO Year
- PBFS N/A
- NYXH 2021
- Fundamental
- Price
- PBFS $13.11
- NYXH $6.24
- Analyst Decision
- PBFS
- NYXH Strong Buy
- Analyst Count
- PBFS 0
- NYXH 3
- Target Price
- PBFS N/A
- NYXH $15.00
- AVG Volume (30 Days)
- PBFS 23.1K
- NYXH 159.3K
- Earning Date
- PBFS 08-08-2025
- NYXH 08-18-2025
- Dividend Yield
- PBFS N/A
- NYXH N/A
- EPS Growth
- PBFS 50.26
- NYXH N/A
- EPS
- PBFS 0.91
- NYXH N/A
- Revenue
- PBFS $91,369,000.00
- NYXH $5,793,306.00
- Revenue This Year
- PBFS N/A
- NYXH $144.57
- Revenue Next Year
- PBFS N/A
- NYXH $244.36
- P/E Ratio
- PBFS $14.40
- NYXH N/A
- Revenue Growth
- PBFS 23.15
- NYXH 2.94
- 52 Week Low
- PBFS $10.60
- NYXH $5.55
- 52 Week High
- PBFS $13.41
- NYXH $11.87
- Technical
- Relative Strength Index (RSI)
- PBFS 60.18
- NYXH 38.74
- Support Level
- PBFS $12.78
- NYXH $6.07
- Resistance Level
- PBFS $13.41
- NYXH $6.47
- Average True Range (ATR)
- PBFS 0.28
- NYXH 0.42
- MACD
- PBFS 0.02
- NYXH -0.01
- Stochastic Oscillator
- PBFS 67.39
- NYXH 19.01
About PBFS Pioneer Bancorp Inc.
Pioneer Bancorp Inc is involved in providing banking services. These services include Personal services such as Checking, Savings, eBanking Cards, and Business services such as Business Deposit and operating Accounts, Business eBanking, and Business loans. Some of the other services of the company include Government Banking, Wealth Management, Benefits Consulting and Insurance.
About NYXH Nyxoah SA
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.